Urinary catalytic iron in obesity.
Catalytic iron, also known as labile iron, consists of chemical forms that can participate in redox cycling. This property makes iron potentially hazardous by enabling it to participate in the generation of reactive iron-oxygen complexes such as ferryl and perferryl ion and powerful oxidant species such as hydroxyl radical produced by the metal-catalyzed Haber-Weiss reaction (9):
[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]
Our bodies contain as much as 3-5 g of total iron, but the pool of labile iron that can be measured (10) is estimated to be <70-90 mg. Although a protective effect of iron chelators in animal models of cardiovascular and kidney disease was demonstrated more than 2 decades ago, the importance of labile iron in several disease states as well as potential sources of labile iron are only now beginning to be recognized.
There are 2 broad lines of evidence for the role of labile iron in different disease states: that it is increased, and that iron chelators provide a protective effect, thus supporting a cause-effect relationship. Such evidence has been reported in a variety of diseases including acute and chronic kidney disease (11, 12), CVD (13-15), and neurodegenerative disorders (16, 17). Labile iron therefore seems to be a common link of cellular injury. We have postulated that labile iron is the common-path physiological link that ties together the disorders of obesity, DM (18), CVD, and CKD. We have previously reported an increase of catalytic iron in patients with diabetic nephropathy (11) and in patients with other forms of CKD. The purpose of this study was to test the hypothesis that urinary catalytic iron is increased in obese patients who are without overt renal impairment and DM.
Research Design and Methods
In a random, stratified manner we selected 200 individuals between the ages of 18 and 70 years (100 obese and 100 nonobese; 50 men and women in each group). The study participants were selected from outpatient clinic and community settings and were participants in an ongoing cross-sectional study to investigate the endo-cannabinoid system in obesity. Our participant population groups were defined as follows: BMI [less than or equal to] 27 kg/[m.sup.2] (control nonobese group) and [greater than or equal to] 30 kg/[m.sup.2] (obese group). For the purpose of this substudy examining catalytic iron, we excluded individuals who were pregnant or had DM or an estimated glomerular filtration rate <60 mL/min. The diagnosis of DM for exclusion purposes was made on the basis of medical history of such a diagnosis, use of DM medications, or fasting blood glucose concentration of >126 mg/dL (>7.0 mmol/L).
The study protocol was approved by an institutional review board, and all study participants gave informed consent. The participants underwent a history and physical examination and submitted blood while in a fasting state. During the study participant's clinic visit for the research study a random fasting spot urine sample was collected and kept in ice until it was divided into aliquots which were put into cryo-vials (within 30 min). These samples were snap frozen immediately and stored at -70[degrees]C for additional analysis. One patient in the control group and 3 patients in the obese group had known coronary heart disease, according to data from the patient history. A detailed history of each patient's medications, including over-the-counter medications, was obtained. One individual in each group was on an iron supplement, and 13 individuals in each group took multivitamins on a daily basis. One patient in the obese group and 2 patients in the control group stated that they took vitamin C. Nonsteroidal antiinflammatory drug use was reported by 11 patients in the obese group and 8 patients in the control group. Five patients in the control group and 5 patients in the obese group had urine microalbumin/creatinine ratios (UMACR) >30. There were 45 women who were postmenopausal (13 in the control group, and 32 in the obese group). None of the obese postmenopausal women were on hormone replacement therapy. In the control group, 12 postmenopausal women were on hormone replacement therapy. There were 4 individuals in the control group and 12 individuals in the obese group who were on lipid-lowering agents. The characteristics of the control and the obese groups are shown in Table 1.
URINARY CATALYTIC IRON TEST
The bleomycin-detectable iron (BDI) assay is based on the observation that the antitumor antibiotic bleomycin, in the presence of iron salt and a suitable reducing agent, binds to and degrades DNA, with the formation of a product that reacts with thiobarbituric acid to form a chromogen. The assay detects iron complexes capable of catalyzing free-radical reactions in biological samples. We tested for the reproducibility and intra- and interassay variability and found them to be acceptable according to standards, as described previously (19-21). For the present study, the within-run and total SDs of the modified urinary BDI assay were determined by following the analytical evaluation method of Linnet and Boyd (22). Two replicates per specimen per run, and 2 runs per day for 20 days were performed for the analysis, as described in CLSIEP5-T (23). For measurement of urinary BDI in the middle range, the intraassay CV was 1.46% and the interassay CV was 19.25%. The initial measurement of catalytic iron was made in micromoles per liter. Then it was adjusted for urine creatinine concentration, and the results were expressed as the ratio of urinary BDI to creatinine (UBDI/Cr) in units of nanomoles per milligram of urine creatinine. The urine albumin was measured by use of the Nyco Card (Axis Shield) kit and expressed as micrograms per milligram of urine creatinine. We used the CR-S synchron (Beckman Coulter) creatinine estimation kit for the measurement of urine creatinine by the Jaffe kinetic method. The analysis was done in a Synchron CX5 Pro Beckman Coulter fully automated clinical chemistry analyzer, and the measured creatinine was expressed in milligrams per deciliter. Plasma glucose was measured by spectrophotometry. Plasma ferritin was measured by the clinical laboratory at the Central Arkansas Veterans Healthcare System using a 2-site immunoenzymatic sandwich assay with a Beckman-Coulter Unicell DXI 800.
MAIN OUTCOMES AND MEASURES
Urinary microalbumin, urinary creatinine, plasma ferritin, and total urinary catalytic iron (BDI) were measured, and UMACR and UBDI/Cr were calculated.
Descriptive statistics for numerical variables are provided. Unpaired Student t-tests were performed for comparisons of mean values between any 2 groups. We used [chi square] tests and, when necessary, Fisher exact tests for testing differences in frequencies of categorical variables between any 2 or more groups. Pearson correlation coefficients were calculated for associations between 2 numerical measures. Ordinary multiple linear regression models were fitted to assess associations between the main outcome measures and various covariates. In such models, statistical significance of a particular covariate on the outcome variable is evaluated after effects of other covariates are already taken into account. In the present study, owing to the skewness of the outcome measures, their log-transformed scales were used as the dependent variables in the regression analysis to better satisfy the normal distribution assumption. The covariates considered in multiple linear regression models were age, race, gender, obesity status, waist-to-hip ratio (WHR), systolic blood pressure, diastolic blood pressure, total cholesterol, HDL cholesterol, LDL cholesterol, glucose, plasma ferritin, and renal function measures such as serum creatinine and UMACR. Stepwise variable-selection procedures were used to select covariates with the most important effect on the outcomes. A subgroup analysis was performed in the female participants to assess the effect of menopause on the outcome by fitting a multiple regression model with menopause (yes/no) in addition to all aforementioned covariates. For all the statistical analysis, a P value of 5% or less was considered statistically significant. SAS 9.2 for Windows was used to analyze the data.
Urinary catalytic iron was significantly higher among the obese individuals compared to the nonobese individuals. In the obese group, the mean UBDI/Cr was 463 nmol/mg (95% CI, 343-582 nmol/mg) [52.3 nmol/ [micro]mol (95% CI, 38.8-65.8 nmol/[micro]mol)], which was significantly greater than the mean UBDI/Cr in the control groups, which was 197 nmol/mg (95% CI, 141-253 nmol/mg) [22.3 nmol/[micro]mol (95% CI, 15.9-28.6 nmol/[micro]mol)] P < 0.001. Among the obese individuals, 51% had UBDI/Cr >253 nmol/mg (28.6 nmol/[micro]mol), the upper limit of the 95% CI. Among these patients the mean (SD) UMACR was 8.47 (8.43) [micro]g/mg. Summaries of other characteristics of the 2 groups are listed in Table 1.
Pearson correlation coefficients were computed to detect possible associations between urinary catalytic iron (both on its original scale and log-transformed scale) and individual numerical measures. In particular, no correlation was observed between the UMACR and excretion of catalytic iron in the urine (r = -0.02, P = 0.74). These associations were reevaluated in a full linear regression analysis in which all the covariates were present in the model simultaneously. This model was significant, with an overall P = 0.01. No significant difference was observed in UBDI/Cr between the obese and the control groups, whether age was categorized into quartiles or actual age was used. A stepwise model selection was performed using the inclusion/exclusion criterion of [alpha] = 5%. This overall reduced stepwise selection model was significant, with P < 0.0001. Two variables, obesity status and WHR, were significant (Table 2) with P = 0.001 and P = 0.03, respectively. Comparison of the UBDI/Cr between the postmenopausal (n = 44) and premenopausal (n = 101) women revealed no significant difference [331 (486) nm/mg vs 436 (656) nm/mg; P = 0.35].
Plasma ferritin concentrations were available in a subset of the patients. Ferritin measurements were not normally distributed in this population. The mean plasma ferritin in the control group did not differ significantly from that in the obese group (64.6 vs 85.6 [micro]g/L, respectively; P = 0.12). No relationship was observed between plasma ferritin and UBDI/Cr (r = -0.0838; P = 0.2469).
Among the obese individuals, 52 patients had metabolic syndrome and 48 patients did not, according to the definition of the National Cholesterol Education Program Adult Treatment Panel III report (24). In post hoc analysis, in individuals with metabolic syndrome UBDI/Cr and UMACR were not found to be significantly different from values seen in individuals without metabolic syndrome (Table 3). No significant difference in plasma ferritin concentrations was seen between study participants with the metabolic syndrome and those without the metabolic syndrome [80.3 (98.4) vs 80.6 (69.9) [micro]g/L; P = 0.9]. The mean UBDI/Cr was slightly higher in obese black individuals (492 nmol/mg; 95% CI, 287-697 nmol/mg), [55.6 nmol/[micro]mole (95% CI, 32.4-78.8 nmol/[micro]mol] compared to obese white individuals (458 nmol/mg; 95% CI, 305-611 nmol/mg) [51.7 nmol/[micro]mol (95% CI, 34.5-68.9 nmol/[micro]mol)], and in obese women (mean, 507 nmol/mg; 95% CI, 357-657 nmol/mg) [57.3 nmol/[micro]mol of urine creatinine (95% CI, 40.3-74.2 nmol/[micro]mol)] compared to obese men (315 nmol/mg; 95% CI, 192-466 nmol/mg) [37.2 nmol/[micro]mol; (95% CI, 21.7-52.7 nmol/[micro]mol)]. However, these differences were not statistically significant. As shown in Table 3, no significant difference was observed in the UBDI/Cr between patients with UMACR >30 in the control and the obese groups (mean, 333.4 vs 203.2 nmol/mg, respectively).
The results of this study demonstrate that urinary catalytic iron is increased in obese individuals compared with nonobese individuals. This increase is independent of age and hypertension. As expected, significant mean differences were observed between the control and obese groups for variables such as glucose, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides (Table 1). After we adjusted for covariates by using multiple regression analysis, the only factors that remained associated with increased UBDI/Cr were obesity and WHR. Individuals in the obese group in our study had considerably higher HDL cholesterol concentrations than expected. Twelve of the 100 obese individuals were on lipid-lowering agents. Because microalbuminuria is used as an early biomarker of kidney disease and CVD, and urine microalbumin concentrations are above the reference interval in some obese individuals, we measured urine microalbumin in the study participants. We found no correlation between UBDI/UCr and UMACR results in our study, possibly owing to the variations in the values of both UMACR and UBDI/UCr. Limitations of a small sample size also may be part of the explanation for this lack of correlation.
Iron has been implicated recently in a variety of disease states. For example, high body-iron stores also have been linked to insulin resistance (25, 26), metabolic syndrome (25, 27-29), and diabetes (18). However, it should be emphasized that epidemiological data have provided conflicting results, with results of several reported studies indicating an association between iron stores and progression of carotid atherosclerosis or acute myocardial infarction (30, 31), whereas other study results have provided evidence against such an association (32, 33). Perhaps an explanation is that iron status per se does not reflect the susceptibility to disease but rather it is the iron available to catalyze free-radical reactions that is important (19). Similarly, iron has been associated with CVD (15, 34). Our results did not show any difference in urinary catalytic iron between obese individuals with and those without metabolic syndrome.
On the basis of results of animal studies and limited preliminary human studies, catalytic iron has been causatively linked to kidney disease (11, 12) and CVD (13-15). We therefore believe that it is of some interest to report the observation that catalytic iron is increased in obese individuals. There was a small but statistically significant difference in mean age between our obese and control groups. However, we found no significant difference in UBDI/Cr when compared across age quartiles between the obese and the control groups. Similarly we found no significant difference in UBDI/Cr between the postmenopausal and premenopausal women. These are limited, preliminary observations and there is insufficient information to date to enable us to understand the importance of the relationship of this observation to microalbuminuria.
Similarly, although an increase in plasma ferritin has been described in patients with metabolic syndrome (29, 35), the high ferritin is more likely to be a reflection of an acute-phase reactant (related to the chronic inflammatory state) rather than iron stores (36). We have measured the active form of ferric iron because this is what plays a pathological role in DM and its complications, rather than simply reflecting body stores. Serum ferritin concentrations have been reported to be higher in postmenopausal women compared to premenopausal women, in part due to cessation of menses (37).
Previous studies have shown high urinary catalytic iron in DM (38), CKD (38), and CVD (13). The source of increased iron in the kidney is not yet well understood. Urinary transferrin has been suggested as a source by Alfrey et al. (39). Glomerular permeability-selectivity impairment due to injury leads to the movement of proteins such as transferrin into the urinary space. At a pH below 6.5, iron has been shown to be dissociated from transferrin. While urine courses along the nephron, and as the pH decreases, iron is released from transferrin (39, 40), providing a source of iron that could act on renal tubular epithelial cells or be reabsorbed into the tubules. In an in vivo study, administration of an iron chelator, deferoxamine, prevented the increase in BDI in glomeruli and provided protection against proteinuria in a model of puromycin-aminonucleoside-induced minimal change nephrotic syndrome (21). Administration of an oral iron chelator, Deferiprone (17), effectively suppressed active experimental autoimmune encephalitis.
The BDI assay offers several advantages. The binding of the bleomycin-iron complex to DNA makes the reaction site specific, and interference from antioxidants is rare. Pertinent in this context are the reports (41) that there is no interference from various iron-containing proteins, including transferrin, ferritin, and hemoglobin. Application of the bleomycin assay shows that blood serum and plasma prepared from healthy individuals contains minimal amounts of BDI (9, 13, 41, 42), and only modest amounts are found in the urine (12, 41). Iron-containing proteins such as ferritin, myoglobin, hemoglobin, and cytochrome P-450 do not register in the assay, and thus the assay measures only iron capable of catalyzing free-radical reactions (9, 19-21, 42). Thus the BDI assay offers a major advantage over measuring ferritin, which gives no indication of how much iron is available to participate in free-radical reactions, and may also be altered in response to inflammation.
Our study results demonstrate that high urinary catalytic iron in obesity provides a potential underlying biochemical explanation for the known clinical associations of obesity with cardiovascular and kidney diseases, independent of DM. Our data are consistent also with previous data suggesting that oxidative stress may be one of the underlying factors in the development of comorbidities of obesity (28, 38), and catalytic iron may be a marker of oxidative stress.
One of the limitations of our results is that they are derived from a cross-sectional study. We do not have data on plasma iron or hemoglobin concentrations among our study participants. We measured plasma ferritin in our patients and found a mild increase in the obese groups, with the data being skewed because some individuals had much higher concentrations of ferritin, which is compatible with data in the literature (43). However, we found no correlation between UBDI/Cr and plasma ferritin. The latter is well known to be an acute-phase reactant and may reflect acute or chronic inflammation. Our animal studies have indicated that catalytic iron concentrations in tissues are not related to iron stores (19). There was very minimal use of over-the-counter or prescription forms of iron, vitamins, and antioxidants among the participants in our study. On the other hand there are no data to suggest that consumption of such substances is likely to be different in obese than nonobese individuals.
In summary, we have demonstrated that urinary catalytic iron is increased in obese individuals compared to nonobese individuals independently of other comorbidities and plasma ferritin. Because this abnormality is common-path physiologically linked to oxidative stress and could be a hallmark of tissue injury, additional research is required to determine if these changes are associated with the long-term complications of obesity.
Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.
Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:
Employment or Leadership: None declared.
Consultant or Advisory Role: None declared.
Stock Ownership: None declared.
Honoraria: None declared.
Research Funding: T.K. Thethi, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, award number K12HD043451; V. Fonseca, National Institutes of Health (ACCORD, TINSAL-2D), the American Diabetes Association, and the Tullis-Tulane Chair of Diabetes. Funding for this study is provided by the Tulane University Phase II Research Enhancement Fund and is supported by the Clinical and Translational Research Center. Diabetes research at Tulane University Health Sciences Center is supported in part by the Susan Harling Robinson Fellowship in Diabetes Research and the Tullis-Tulane Alumni Chair in Diabetes.
Expert Testimony: None declared.
Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.
Acknowledgments: The authors thank Cindy Reid of the University of Arkansas for Medical Sciences for technical editing assistance.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health.
(1.) World Health Organization. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ (Accessed December 2010).
(2.) Hossain P, Kawar B, El NM. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med 2007;356:213-5.
(3.) Abrass CK. Overview: obesity: what does it have to do with kidney disease? J Am Soc Nephrol 2004;15:2768-72.
(4.) Agnani S, Vachharajani VT, Gupta R, Atray NK, Vachharajani TJ. Does treating obesity stabilize chronic kidney disease? BMC Nephrol 2005;6:7.
(5.) Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-74.
(6.) Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17: 1695-702.
(7.) Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep 2007;7:449-53.
(8.) Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. J Am Soc Nephrol 2008; 19:4-7.
(9.) Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
(10.) Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med 2002;33:1037-46.
(11.) Shah SV, Rajapurkar M, Houser M. The role of labile iron in acute kidney injury. US Nephrol 2008;52-5.
(12.) Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;18:16-28.
(13.) Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention 2009;5:336-42.
(14.) Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A, et al. Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care 2004;27: 2730-2.
(15.) Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718-23.
(16.) Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110:401-8.
(17.) Mitchell KM, Dotson AL, Cool KM, Chakrabarty A, Benedict SH, LeVine SM. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler 2007;13:1118-26.
(18.) Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007;30:1926-33.
(19.) Baliga R, Ueda N, Shah SV. Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J 1993;291(Pt 3):901-5.
(20.) Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int 1998;54:1562-9.
(21.) Ueda N, Baliga R, Shah SV. Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome. Kidney Int 1996;49:370-3.
(22.) Linnet K, Boyd JC. Selection and analytical evaluation of methods with statistical techniques. In: Burtis CA, Ashwood EK, Bruns DE, eds. Teitz textbook of clinical chemistry and molecular diagnostics. St. Louis: Saunders; 2006. p 353-407.
(23.) CLSI/NCCLS. User evaluation of precision performance of clinical chemistry devices. CLSI/NCCLS tentative guideline EP5-T. Wayne (PA): CLSI/NCCLS; 1984.
(24.) Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
(25.) Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf) 2003;58:380-5.
(26.) Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, et al. Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care 1997; 20:426-8.
(27.) Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De MG, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005;28: 2061-3.
(28.) Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, RicartW. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002;51:1000-4.
(29.) Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8.
(30.) de Valk B, Marx JJM. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999; 159:1542-8.
(31.) Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96:3300-7.
(32.) Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994;89:2915-8.
(33.) Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 1999;99:852-4.
(34.) Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003;41:S80-3.
(35.) Vari IS, Balkau B, Kettaneh A, Andre P, Tichet J, Fumeron F, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007;30:1795-801.
(36.) Thurnham DI, McCabe LD, Haldar S, Wieringa FT, Northrop-Clewes CA, McCabe GP. Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis. Am J Clin Nutr 2010;92:546-55.
(37.) Masse PG, Dosy J, Cole DE, Evroski J, Allard J, D'Astous M. Is serum ferritin an additional cardiovascular risk factor for all postmenopausal women? Ann Nutr Metab 2004;48:381-9.
(38.) Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD. Diabetic nephropathy in hypertransfused patients with beta-thalassemia. The role of oxidative stress. Diabetes Care 1998;21:1306-9.
(39.) Alfrey AC. Toxicity of tubule fluid iron in the nephrotic syndrome. Am J Physiol 1992;263: F637-F641.
(40.) Cooper MA, Buddington B, Miller NL, Alfrey AC. Urinary iron speciation in nephrotic syndrome. Am J Kidney Dis 1995;25:314-9.
(41.) Santini SA, Marra G, Giardina B, Cotroneo P, Mordente A, Martorana GE, et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 1997;46:1853-8.
(42.) Gutteridge JM, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of 'free' iron in biological systems by using bleomycin-dependent degradation of DNA. Biochem J 1981;199:263-5.
(43.) Yanoff LB, Menzie CM, Denkinger B, Sebring NG, McHugh T, Remaley AT, Yanovski JA. Inflammation and iron deficiency in the hypoferremia of obesity. Int J Obes (Lond) 2007;31:1412-9.
Tina K. Thethi,  * Kaushik Parsha,  Mohan Rajapurkar,  Banibrata Mukhopadhyay,  Sudhir Shah,  C. Lillian Yau,  Shanker Japa,  and Vivian Fonseca 
 Tulane University Health Sciences Center, New Orleans, Louisiana,  Muljibhai Patel Society for Research in Nephro-Urology, Nadiad, Gujarat, India,  University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas,  School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana
 Nonstandard abbreviations: DM, type 2 diabetes mellitus; CVD, cardiovascular disease; CKD, chronic kidney disease; UMACR, urine microalbumin/creatinine ratio; BDI, bleomycin-detectable iron; UBDI/Cr, urinary BDI/creatinine ratio; WHR, waist-to-hip ratio.
* Address correspondence to this author at: 1430 Tulane Ave, SL-53, New Orleans, LA 70112. Fax 504-988-6271; e-mail firstname.lastname@example.org.
Received August 8, 2010; accepted December 8, 2010.
Previously published online at DOI: 10.1373/clinchem.2010.154757
Table 1. Characteristics of the participants in the 2 groups. (a) Controls Obese (n = 100) individuals P (n = 100) BMI 22.9(2.5) 38.5 (6.5) <0.001 WHR 0.8(0.1) 0.9(0.1) <0.001 Waist circumference, inches 31.2 (5.5) 44.7 (6.2) <0.001 Age, y 37.4 (13.7) 43.9 (12.6) 0.006 Glucose, mg/dL (b) 65.7 (2.5) 79.3 (24.2) <0.001 Systolic blood pressure, 117.5 (13.0) 126.7 (15.9) <0.001 mm Hg Diastolic blood pressure, 72.1 (10.6) 80.4 (10.7) <0.001 mm Hg Total cholesterol, mg/dL 182.2 (37.9) 186.1 (34.8) 0.46 LDL, mg/dL 100.6 (31.6) 111.6 (31.21) 0.02 HDL, mg/dL 65.7 (17.7) 51.6 (14.1) <0.001 Triglycerides, mg/dL 84.5 (70.4) 118.1 (68.3) 0.001 Serum creatinine, mg/dL 0.9 (0.4) 0.8 (0.3) 0.32 Log UBDI/Cr 3.5 (2.5) 4.9(2.2) <0.001 Plasma ferritin, [micro]g/L 63.6 (64.6) 80.4 (85.6) 0.12 UMACR, [micro]g/mg 11.5 (13.0) 10.7 (10.4) 0.34 Log UMACR 2.1 (0.8) 2.1 (0.9) 0.78 UBDI/Cr in individuals with 203.4 (231.3) 333.4 (283.6) 0.47 UMACR >30 nm/mg (a) Results are expressed as mean (SD). (b) To convert concentrations to millimoles per liter, multiply by 0.0555 for glucose; by 0.0259 for cholesterol, LDL, and HDL; by 0.0113 for triglycerides; and by 0.0884 for creatinine. Table 2. Detailed information on the parameter estimates from the linear regression model. Parameter estimates Variable Parameter SE t Pr (a) > estimate [absolute value of t] Intercept -0.36 1.78 -0.20 0.84 Obesity status 1.22 0.38 3.24 0.001 WHR 4.64 2.13 2.17 0.03 (a) Pr, probability. Table 3. Urinary catalytic iron in various groups. (a) UBDI/Cr, P nm/mg Blacks, obese group (n = 41) 492 (651) 0.78 Whites, obese group (n = 57) 476 (576) Blacks, control group (n = 17) 184 (292) 0.83 Whites, control group (n = 81) 200 (283) With the metabolic syndrome (n = 52) 543 (623) 0.2 (b) Without the metabolic syndrome (n = 48) 389 (579) Premenopausal women (n = 101) 331 (486) 0.35 Postmenopausal women (n = 44) 436 (656) Males, obese group (n = 23) 315(310) 0.06 Females, obese group (n = 77) 507 (661) Males, control group (n = 31) 191 (251) 0.88 Females, control group (n = 68) 200 (297) (a) Values are presented as mean (SD). (b) Among the obese participants only.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Endocrinology and Metabolism|
|Author:||Thethi, Tina K.; Parsha, Kaushik; Rajapurkar, Mohan; Mukhopadhyay, Banibrata; Shah, Sudhir; Yau, C.|
|Date:||Feb 1, 2011|
|Previous Article:||Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb [A.sub.1c]).|
|Next Article:||Computational methods are significant determinants of the associations and definitions of insulin resistance using the homeostasis model assessment...|